IOVA News and Press, Iovance Biotherapeutics Inc. From 09/15/23

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is one today's most active stocks by volume. So far today, approximately 30.7M shares of Iovance Biotherapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 4.19M shares. Iovance Biotherapeutics, Inc., a clinical-stage biot...

2023-09-15 10:03:47 ET More on Iovance Biotherapeutics Seeking Alpha’s Quant Rating on Iovance Biotherapeutics Historical earnings data for Iovance Biotherapeutics Financial information for Iovance Biotherapeutics Iovance Biotherapeutics: Why The Stock...

2023-09-15 08:10:20 ET Iovance Biotherapeutics ( NASDAQ: IOVA ) +16% . Novonix  ( NVX ) +15% Achieves Key Milestones and Establishes Pathway to Profitable Anode Material Production in the U.S. Nikola Corporation ( NKLA ) +14% . Yunhong CTI ...

2023-09-15 05:17:07 ET Related stories Arm Holdings IPO Is Too Hot ARM Holdings: IPO Valuation Expensive Arm IPO: How The Failed Nvidia Takeover Affects The Upcoming Offering Arm Holdings: Don't Bail Out This Private Equity Giant SoftBank's Arm Holdin...

Priority Review Continues with Successful Facility Inspections Completed, no Major Review Issues FDA Extends PDUFA Date to February 24, 2024 on Resource Constraints and Agrees to Work with Iovance to Expedite Remaining Review SAN CARLOS, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE)...

2023-09-14 17:08:06 ET Summary Iovance stock has been selling off despite the potential for a historic first approval for a solid-tumor targeting cell therapy. The market has doubts about the durability, efficacy, and safety of cell therapies targeting solid tumors. Iovance ha...

2023-09-14 16:36:28 ET Shares of Iovance Biotherapeutics (NASDAQ: IOVA) fell more than 13% on Thursday. The biotech company, which specializes in using tumor-infiltrating lymphocyte (TIL) therapies to fight cancer, has seen its shares drop by more than 25% so far this year, hitt...

2023-09-14 11:57:47 ET More on Iovance Biotherapeutics Iovance: November PDUFA, But A History Of Delays And Underwhelming Data Iovance Biotherapeutics: Evaluating Recent Developments And FDA Feedback Iovance Biotherapeutics: More Than A One-Shot Wonder Seekin...

SAN CARLOS, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leade...

2023-08-30 16:01:36 ET Summary Iovance Biotherapeutics, Inc. has a deep pipeline of cancer immunotherapies, but has faced delays and issues with duration of response. The company's lead asset, lifileucel, is being tested in multiple trials for different indications. Underwhelm...